WELCOME TO이화여대 AI-사회약학규제과학 연구실

Publications

Papers

> Publications > Papers
Papers
번호제목
97[2026] Health-related quality of life in patients with spinal muscular atrophy receiving nusinersen and their caregivers: a cross-sectional study
96[2021-2022] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
95[2023-2024] Cost-Effectiveness of Fractional Flow Reserve in Patients with Acute Myocardial Infarction and Multivessel Disease: Prespecified Analysis of FRAME-AMI Trial
94[2025] Safety of Potassium-Competitive Acid Blockers Compared with Proton Pump Inhibitors in Patients with Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta-analysis
93[2025] HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
92[2023-2024] 디지털의료제품 관련 국내외 규제 비교 분석을 통한 규제적 측면에서의 발전 방안 제언
91[2023-2024] 국내 기구축 레지스트리의 운영 특성 및 의약품의 규제과학적 의사결정 활용 현황 조사
90[2023-2024] 시각장애인의 의약품 안전 사용을 위한 점자 표기의 필요성 및 정보 전달 방법에 관한 주제 범위 문헌고찰
89[2023-2024] Stakeholders’ perspectives on the assessment and negotiation policy for indication expansion of listed drugs
87[2023-2024] Comparison and Analysis of Domestic and Foreign Guidelines for Braille Labeling of Drugs
85[2023-2024] Clinical and Financial Features of Dementia as a Comorbidity in Korean Patients with Parkinson’s Disease: A National Database Cross-sectional Study
84[2023-2024] 코로나19의 사회경제적 부담과 영향에 대한 체계적 문헌고찰
82[2023-2024] Cost-Effectiveness of Intravascular Imaging-Guided Complex PCI: Prespecified Analysis of RENOVATE-COMPLEX-PCI Trial
81[2023-2024] Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean Setting
80Cost-utility Analysis Methods of Androgen Receptor Targeted Agents forMetastatic Hormone-Sensitive Prostate Cancer: A Systematic Review
79[2023-2024] Emicizumab의 효과 및 안전성에 대한 실사용 근거 생성: 체계적 문헌고찰
78[2023-2024] Exploring the health literacy status of people with hearing impairment: a systematic review
77[2023-2024] Effects of the coronavirus disease outbreak on the development of neurological disorders in children: A comparison of the incidence of febrile seizure and epilepsy using an interrupted time-series approach
76[2023-2024] Association between selective serotonin reuptake inhibitor use and developing irritable bowel syndrome through retrospective analysis
75[2023-2024] Hypertension and Insulin Resistance from Prediabetes to Type 2 Diabetes: A 10-Years South Korean Prospective Cohort Study
74[2023-2024] Population health outcomes in South Korea 1990–2019, and projections up to 2040: a systematic analysis for the Global Burden of Disease Study 2019
73[2023-2024] 면역관용요법을 시행 중인 A형 혈우병 환자에서 에미시주맙의 예방적 사용요법에 대한 체계적 문헌고찰
72[before 2021] Clinical and economic burden of visual impairment in an aging society of South Korea
71[before 2021] Prevalence and socio-economic burden of heart failure in an aging society of South Korea
70[before 2021] Investigating potential problems in comparator drug selection for cost-effectiveness assessment of newly approved drugs for reimbursement decision
69[before 2021] Patient Awareness of Cataract and Age-related Macular Degeneration among the Korean Elderly: A Population-based Study
68[2026] Cost-Effectiveness of Various First-Line Helicobacter pylori Eradication Regimens in Korea: Analysis of the Korean Registry on the Current Management of H. pylori (K-Hp-Reg)
67[before 2021] Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: A population-based nested case-control study
66[before 2021] Nationwide epidemiologic study of atypical antipsychotic use among pediatric population with mental illness in Korea
65[before 2021] The incremental economic burden of heart failure: a population-based investigation from South Korea
64[before 2021] A Systematic Review on Economic Evaluation of Rotavirus Vaccination
63[before 2021] 딥러닝 기반 항생제 내성균 감염 예측
62[before 2021] Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study
61[before 2021] Public preferences for corporate social responsibility activities of the pharmaceutical industry: Empirical evidence from Korea
60[before 2021] Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain–Barré Syndrome
59[before 2021] Socioeconomic impact of the rotavirus vaccine in Korea: Comparing the epidemiologic and economic characteristics of rotavirus gastroenteritis before and after the introduction of vaccines
58[before 2021] Signals and trends of Guillain–Barré Syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems
57[before 2021] Incidence of Guillain–Barré Syndrome is not associated with influenza vaccination in the elderly
55[before 2021] Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial
54[before 2021] Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older
53[2021-2022] Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis B to prevent liver disease progression
52[2021-2022] Epidemiological features and economic burden of Guillain–Barré Syndrome in South Korea: a nationwide population-based study
51[2021-2022] Association between depression and antibiotic use: analysis of population-based National Health Insurance claims data
50[2021-2022] Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1
49[2021-2022] ALK-양성 비소세포성 폐암 환자 대상 Alectinib과 Crizotinib의 무진행 생존기간 효능 비교: 체계적 문헌 고찰 및 메타분석
48[2021-2022] Cost-Effectiveness of Chronic Hepatitis C screening and treatment
47[2021-2022] Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level<2,000 IU/mL
46[2021-2022] Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
45[2021-2022] Gender Difference in Health-Related Behaviors associated with Metabolic Status-Obesity Phenotypes among Korean Adults
44[2021-2022] Focus Group Interview of Stakeholders to Derive Checklists for Future Real-world Data and Real-world Evidence Use in Regulatory Decision Making for Drugs
43[2021-2022] A Micro-Costing Analysis of Flexible Bronchoscopic Intubation in a Korean Tertiary Hospital
42[2021-2022] Real-world clinical features, health-care utilization, and economic burden in decompensated cirrhosis patients: A national database
41[2021-2022] Comparison of netarsudil/latanoprost therapy with latanoprost monotherapy for lowering intraocular pressure: a systematic review and meta-analysis
40[2021-2022] 적절한 폐의약품 처리 방법에 대한 약대생의 인식 및 지식 설문조사
38[2021-2022] New evidence of oral branched-chain amino acid supplementation on the prognosis of patients with advanced liver disease
37[2021-2022] Long-term cost-effectiveness of fractional flow reserve-based percutaneous coronary intervention in stable and unstable angina
36[2026] Optimizing Hepatitis C Micro-elimination in Forensic Psychiatric Settings: Cost-effectiveness of Screening Strategies in Korea
35[2026] Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework
34[2026] Association Between Cancer Stage and Parenting Self-Efficacy in Breast Cancer Survivors: A Survey of a Triple-Negative Breast Cancer Community
32[2026] Nationwide Insights on Early Childhood Neurodevelopment During a Global Health Crisis: Evidence from COVID-19 in South Korea
31[2025] Treatment Patterns and Survival Outcomes in Korean Patients with Metastatic Hormone-Sensitive Prostate Cancer in a Real-World Setting
30[2025] Analysis of Medication Adherence and Influencing Factors in Patients With Treatment-Resistant Hypertension in South Korea: A Nationwide Retrospective Cohort Study
29[2026] Economic Evaluation of Empirical and Tailored Helicobacter pylori Eradication Strategies including Second-Line Therapy
28[2026] Prostate Cancer in Korea: Nationwide Trends in Prevalence and Medication Use During 2011-2021
27[2026] Risk of Liver and Kidney Adverse Events After Androgen Deprivation Therapy in Prostate Cancer: A Population-Based Retrospective Cohort Study
26[2026] Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD
25[2026] Comparative risk of pneumonia and acute exacerbation between P-CAB and PPI use in patients with COPD and GERD
24[2026] 유전자치료제의 급여 및 재정 지불 모형에 대한 국제 비교 및 정책적 함의
23[2026] Economic Burden of Treatment Resistant Depression in Korea: A 28-Day Health-State-Specific Cost Analysis
22[before 2021] Population-based epidemiology of pediatric patients with treated tic disorders from real-world evidence in Korea
20[2023-2024] Clinical Characteristics and Medical Expenditure in Patients with Chronic Kidney Disease by Consequence of Renal Replacement Therapy
19[2025] A multicenter micro-costing analysis of flexible cystoscopic procedures in Korea
18[2025] Assessing the Risk of Cognitive Impairment associated with Androgen Receptor Targeting Agent Use in Metastatic Prostate Cancer: A Systematic Review of Real-world Data
17[2025] COVID-19 infection in patients with end-stage kidney disease undergoing renal replacement therapies in Korea
16[2025] Clinician guidance in digital therapeutics for panic disorder: Meta-analytic dissection and implications for regulatory framing and scalable deployment
15[2025] Cost-Effectiveness of Tailored vs. Empirical Therapy for H. pylori: A Decision-Tree Analysis
14[2025] Economic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea
13[2025] Incidence and risk of drug-induced interstitial lung disease associated with anti-neoplastic drugs
12[2025] Insignificant difference in medication adherence to dyslipidemia drugs between visually impaired and non-disabled people in South Korea: A nationwide cohort study using claims records
11[2025] Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy
10[2025] Prescription trends of gastric acid suppressants and association with potential adverse events in Korea: a real-world cross-sectional study
9[2025] Risk of Alzheimer's disease and Parkinson's disease following androgen deprivation therapy in a real world nationwide cohort
8[2025] Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness
7[2025] 수원시 거주자의 혈압 및 혈당 인지율의 지역 간 격차와 관련 요인
6[2023-2024] Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease
5[2023-2024] Determinants of immune checkpoint inhibitor use and factors linked to neurological adverse events in Korean lung cancer
4[2023-2024] Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea
3[2023-2024] Kidney replacement therapy trends in end-stage kidney disease patients in South Korea during the COVID-19 pandemic
2[2023-2024] Recent updates on treatment patterns in patients with treated attention-deficit/hyperactivity disorders from a nationwide real-world database in South Korea
1[2023-2024] Unveiling the chasm of economic burden from metastatic prostate cancer through a nationwide retrospective cohort study
Powered by MangBoard | 망보드 스토어